Skip to main content

Repurposing of carbamazepine for treatment of skeletal dysplasia

Objective

Genetic skeletal diseases (GSDs) are an extremely diverse and complex group of rare genetic diseases that affect the development the skeleton. There are more than 450 unique and well-characterised phenotypes that range in severity from relatively mild to severe and lethal forms. Although individually rare, as a group of related genetic skeletal diseases, GSDs have an overall prevalence of at least 1 per 4,000 children, which extrapolates to a minimum of 225,000 people in the 27 member states and candidate countries of the EU. This burden in pain and disability leads to poor quality of life and high healthcare costs.
Metaphyseal chondrodysplasia, type Schmid (MCDS) results from mutations in collagen X and affects <1/100,000 of the population. Mutant collagen X molecules miss-fold during synthesis and are retained within the endoplasmic reticulum (ER) of hypertrophic chondrocytes, thereby causing ER stress. Our extensive pre-clinical studies have shown that carbamazepine (CBZ) can alleviate ER stress caused by the expression of mutant collagen X and restore bone growth in a validated mouse model of MCDS. CBZ is an FDA approved drug used for the treatment of epilepsy
and bipolar disorder and received orphan drug designation by the European Commission for the treatment of MCDS in September 2016.
MCDS-Therapy was originally proposed as a 5-year collaborative project comprising world-renown clinical centres and SMEs to advance the repurposing of CBZ for MCDS (up to the Marketing Authorization Application dossier) through a multicentre and multinational (EU & AUS) clinical trial (Phase1, Phase2/3). MCDS-Therapy also encompasses biomarker
development and health economics assessment studies to deliver, evidence to inform potential further studies of an innovative and affordable (CBZ already exists in a generic form) repurposed therapy for MCDS along with the diagnosis/prognosis tools to personalise the treatment strategy. The original proposal was for completion of this by 2022 however delays associated with the COVID pandemic have resulted in a need to extend the project with completion now forecast by May 2024.

Call for proposal

H2020-SC1-2016-2017

See other projects for this call

Sub call

H2020-SC1-2017-Two-Stage-RTD

Coordinator

UNIVERSITY OF NEWCASTLE UPON TYNE
Net EU contribution
€ 1 960 601,86
Address
Kings Gate
NE1 7RU Newcastle Upon Tyne
United Kingdom

See on map

Region
North East (England) Northumberland and Tyne and Wear Tyneside
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00

Participants (11)

Third-party

Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.

THE NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST
United Kingdom
Net EU contribution
€ 410 287,26
Address
Freeman Hospital, High Heaton
NE7 7DN Newcastle-upon-tyne

See on map

Region
North East (England) Northumberland and Tyne and Wear Tyneside
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Other funding
€ 0,00
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
France
Net EU contribution
€ 99 677,72
Address
55 Boulevard Diderot
75012 Paris

See on map

Region
Ile-de-France Ile-de-France Val-de-Marne
Activity type
Research Organisations
Other funding
€ 0,00
UNIVERSITAIR ZIEKENHUIS ANTWERPEN
Belgium
Net EU contribution
€ 70 376,53
Address
Drie Eikenstraat 655
2650 Edegem

See on map

Region
Vlaams Gewest Prov. Antwerpen Arr. Antwerpen
Activity type
Research Organisations
Other funding
€ 0,00
UNIVERSITAETSKLINIKUM FREIBURG
Germany
Net EU contribution
€ 382 015,88
Address
Hugstetter Strasse 49
79106 Freiburg

See on map

Region
Baden-Württemberg Freiburg Freiburg im Breisgau, Stadtkreis
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00
MURDOCH CHILDRENS RESEARCH INSTITUTE
Australia
Net EU contribution
€ 340 625,00
Other funding
€ 0,00
GUYS AND ST THOMAS' NHS FOUNDATIONTRUST
United Kingdom
Net EU contribution
€ 277 428,75
Address
Westminster Bridge Road
SE1 7EH London

See on map

Region
London Inner London — East Lambeth
Activity type
Research Organisations
Other funding
€ 0,00
BEACON: FOR RARE DISEASES LTD
United Kingdom
Net EU contribution
€ 309 235,00
Address
66 Devonshire Road
CB1 2BL Cambridge

See on map

Region
East of England East Anglia Cambridgeshire CC
Activity type
Research Organisations
Other funding
€ 0,00
ISTITUTO ORTOPEDICO RIZZOLI
Italy
Net EU contribution
€ 571 741,84
Address
Via Di Barbiano 1/10
40136 Bologna

See on map

Region
Nord-Est Emilia-Romagna Bologna
Activity type
Research Organisations
Other funding
€ 0,00
Third-party

Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.

ALMA MATER STUDIORUM - UNIVERSITA DI BOLOGNA
Italy
Net EU contribution
€ 285 433,16
Address
Via Zamboni 33
40126 Bologna

See on map

Region
Nord-Est Emilia-Romagna Bologna
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00
SCIOMICS GMBH
Germany
Net EU contribution
€ 604 030,00
Address
Karl-landsteiner Str. 6
69151 Neckargemund

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Baden-Württemberg Karlsruhe Rhein-Neckar-Kreis
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 0,00
FINOVATIS
France
Net EU contribution
€ 385 937,50
Address
62 Rue De Bonnel
69003 Lyon

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Auvergne-Rhône-Alpes Rhône-Alpes Rhône
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 0,00